Accessibility Menu
Evommune logo

Evommune(NYSE) EVMN

Market Cap$480.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-35%
5 YearN/A
1 YearN/A
1 Month+13%
$12.64
-4.46%
-0.59Today
After hours$12.66+$0.02 (+0.16%)
Evommune last closing stock price
MetricPriceDate
Last closeUSD 12.662026-08-31
Evommune stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.39%USD 13.672026-08-24
1 month+12.53%USD 11.252026-07-31
3 month-36.13%USD 19.822026-06-02
Year to date-26.05%USD 17.122025-12-31
Since inception-34.6%USD 20.232025-11-06

Evommune Financials at a Glance

Market Cap

$480.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$10.00M

Net Income (TTM)

-$94.67M

EPS (TTM)

-$2.83

P/E Ratio

-4.68

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$12.64

Volume

571,962.998

Open

$13.08

Previous Close

$12.66

Daily Range

$12.61 - $13.13

52-Week Range

$10.47 - $33.20

Estimated Earnings Date

Oct 16, 2026

EVMN News

biotech pharma researchers talk lab

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

James HalleyMar 10, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evommune

Evommune makes drugs for people with long-term inflammation. It helps treat itchy skin and painful gut issues. These medicines aim to block signals that cause swelling.

What Is Evommune Building?

  • EVO756: An experimental treatment for skin inflammation and migraine headaches.
  • EVO301: A drug candidate designed for skin rashes and bowel disease.
  • Discovery Programs: Early research efforts targeting the root causes of chronic inflammation.

Partnerships and Key Licenses

  • Acquired a worldwide license for EVO756 from Dermira in December 2020.
  • Partnered with Maruho in September 2023 for drug development in Japan.
  • Licensed EVO301 from AprilBio in June 2024 for global development and sales.
  • Expanded the Maruho deal in March 2024 to include Greater China.
  • Decided to stop developing EVO756 for chronic hives in June 2026.

The Strategy Behind the Science

Evommune focuses on inflammation drivers that current therapies do not address. It utilizes strategic licensing to build a diverse pipeline without starting every project from scratch.

Financial Data and Cash Balance

  • Net loss was $53.9 million for the six months ended June 30, 2026.
  • Research and development expenses reached $43.7 million in the first half of 2026.
  • Cash and investments totaled $288 million as of June 30, 2026.
  • Common stock sales raised $117.1 million in net proceeds during February 2026.
  • Revenue was zero for the six-month period ended June 30, 2026.

How the Company Has Evolved

Evommune has evolved from a startup into a clinical-stage biotechnology developer with multiple mid-stage drug trials. Its strategy relies on licensing external science to build a focused pipeline for inflammatory diseases.

AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

48

CEO

Luis C. Peña

Website

www.evommune.com

Headquarters

Palo Alto, CA 94304, US

EVMN Financials

Key Financial Metrics (TTM)

Gross Margin

96.51%

Operating Margin

-1018.93%

Net Income Margin

-946.68%

Return on Equity

-62.63%

Return on Capital

-39.05%

Return on Assets

-31.35%

Earnings Yield

-21.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$480.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.29M

Volume

571.96K

Avg. Volume

781.90K

Financials (TTM)

Gross Profit

$9.65M

Operating Income

-$101.89M

EBITDA

-$95.78M

Operating Cash Flow

-$74.15M

Capital Expenditure

-$501.00K

Free Cash Flow

-$74.65M

Cash & ST Invst.

$200.79M

Total Debt

$8.11M

Evommune Performance Analysis

Evommune annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 5,000,000N/A
20242024-12-31USD 7,000,00040.0%
20252025-12-31USD 13,000,00085.7%
Evommune sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
Q22026-06-30N/A
Evommune annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -1.13N/A
20242024-12-31USD -2.27100.6%
20252025-12-31USD -2.18-3.8%
Evommune sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3011.1%
Q42025-12-31-125.0%
Q12026-03-3128.9%
Q22026-06-30-39.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$480.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.00M

N/A

Employees

48

N/A

Net Income

-$32.25M

-137.7%

EBITDA

-$34.34M

-160.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$200.79M

+131.3%

Total Debt

$8.11M

-96.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$6.87M

-97.3%

Short Term Debt

$1.24M

+166.0%

Return on Assets

-31.35%

N/A

Return on Invested Capital

-35.82%

N/A

Free Cash Flow

-$20.50M

+21.8%

Operating Cash Flow

-$20.32M

+22.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTVArtiva Biotherapeutics, Inc.
$11.30+1.89%
EYPTEyePoint Pharmaceuticals, Inc.
$4.50+0.45%
OABIOmniAb, Inc.
$4.38-2.01%
CDXSCodexis, Inc.
$1.70+6.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About EVMN

What is the current price of Evommune?

Evommune is trading at $12.66 per share.

What is the 52-week range for Evommune?

Over the past 52 weeks, Evommune has traded between $10.47 and $33.20.

How much debt does Evommune have?

As of the most recent reporting period, Evommune reported total debt of $8.63M.

How much cash does Evommune have on hand?

Evommune reported $60.03M in cash and cash equivalents in its most recent financial results.

What is Evommune’s dividend yield?

Evommune does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services